Drugs / LMB-7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003020 | Sep 1997 → Sep 2000 | central nervous system neoplasm | Duke University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMB-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003020 ↗ |
| Known as | LMB-7 immunotoxin | “RATIONALE: LMB-7 immunotoxin can locate tumor cells and kill them without harming normal cells.” NCT00003020 ↗ |
| Action | Inhibit | “Elongation factor 2 inhibitor” CHEMBL2109307 ↗ |
| Modality | Protein / enzyme biologic | “Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38” NCT00003020 ↗ |
| Route | Intrathecal | “Patients receive LMB-7 intrathecally on days 1, 3, and 5.” NCT00003020 ↗ |
| Target | EEF2 | “Elongation factor 2 inhibitor” CHEMBL2109307 ↗ |